Combination Therapy with Clindamycin and Rifampicin for Hidradenitis Suppurativa: A Series of 116 Consecutive Patients

被引：195

作者：

Gener, G. ^{[1
]}

Canoui-Poitrine, F. ^{[2
,4
,5
]}

Revuz, J. E. ^{[1
,4
]}

Faye, O. ^{[6
]}

Poli, F. ^{[1
]}

Gabison, G. ^{[1
]}

Pouget, F. ^{[1
]}

Viallette, C. ^{[3
]}

Wolkenstein, P. ^{[1
,4
]}

Bastuji-Garin, S. ^{[2
,4
]}

机构：

[1] Univ Paris 12, Fac Med, Grp Henri Mondor Albert Chenevier, AP HP,Serv Dermatol, Creteil, France

[2] Univ Paris 12, Fac Med, Grp Henri Mondor Albert Chenevier, AP HP,Serv Sante Publ, Creteil, France

[3] Univ Paris 12, Grp Henri Mondor Albert Chenevier, AP HP, Unite Rech Clin, Creteil, France

[4] Univ Paris 12, Fac Med, LIC EA Creteil 4393, Creteil, France

[5] Univ Lyon 1, Hosp Civils Lyon, Pole IMER, F-69365 Lyon, France

[6] CNAM Ex Inst Marchoux, Dept Dermatol, Bamako, Mali

来源：

DERMATOLOGY | 2009年 / 219卷 / 02期

关键词：

Hidradenitis suppurativa; Rifampicin; Clindamycin; Sartorius score; Quality of life; COAGULASE-NEGATIVE STAPHYLOCOCCI; INFLIXIMAB; EFFICACY; ETANERCEPT; PREVALENCE; ADALIMUMAB; LESIONS; CELLS; MICE;

D O I：

10.1159/000228334

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Antibiotics are frequently used to treat hidradenitis suppurativa (HS); however, few data on their efficacy are available. Objective: To evaluate the efficacy of a combination of systemic clindamycin (300 mg twice daily) and rifampicin (600 mg daily) in the treatment of patients with severe HS. Methods: Patients (n = 116) who received this combination were studied retrospectively. The main outcome measure was the severity of the disease, assessed by the Sartorius score, before and after 10 weeks of treatment. Results: The Sartorius score dramatically improved at the end of treatment (median = 29, interquartile range = 14.5, vs. median = 14.5, interquartile range = 11; p < 0.001), as did other parameters of severity as well as the quality of life score. Eight patients (6.9%) stopped the treatment because of side effects. Conclusion: The combination of clindamycin and rifampicin is effective in the treatment of severe HS. Copyright (C) 2009 S. Karger AG, Basel

引用

页码：148 / 154

页数：7

共 38 条

[1] INVITRO INTERACTION BETWEEN RIFAMPIN AND CLINDAMYCIN AGAINST PATHOGENIC COAGULASE-NEGATIVE STAPHYLOCOCCI [J].

ARDITI, M ;

YOGEV, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (02) :245-247

[2] Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa [J].

Brook, I ;

Frazier, EH .

JOURNAL OF MEDICAL MICROBIOLOGY, 1999, 48 (01) :103-105

[3] Folliculitis decalvans [J].

Brooke, RCC ;

Griffiths, CEM .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (01) :120-122

[4]

CANOUIPOITRINE F, 2009, J AM ACAD D IN PRESS

[5] TOPICAL TREATMENT OF HIDRADENITIS SUPPURATIVA WITH CLINDAMYCIN [J].

CLEMMENSEN, OJ .

INTERNATIONAL JOURNAL OF DERMATOLOGY, 1983, 22 (05) :325-328

[6] Etanercept: effective in the management of hidradenitis suppurativa [J].

Cusack, C ;

Buckley, C .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (04) :726-729

[7] Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients [J].

Fardet, Laurence ;

Dupuy, Alain ;

Kerob, Delphine ;

Levy, Annabelle ;

Allez, Matthieu ;

Begon, Edouard ;

Bachelez, Herve ;

Morel, Patrice ;

Lebbe, Celeste .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (04) :624-628

[8] Infliximab for the treatment of hidradenitis suppurativa [J].

Fernandez-Vozmediano, J. M. ;

Armario-Hita, J. C. .

DERMATOLOGY, 2007, 215 (01) :41-44

[9] An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa [J].

Giamarellos-Bourboulis, E. J. ;

Pelekanou, E. ;

Antonopoulou, A. ;

Petropoulou, H. ;

Baziaka, F. ;

Karagianni, V. ;

Stavrianeas, N. ;

Giamarellou, H. .

BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (03) :567-572

[10]

Hurley H.J., 1989, Dermatologic surgery, principles and practice

← 1 2 3 4 →